Objectives To demonstrate clinical efficacy in reducing the ocular symptoms of SAR using mometasone furoate nasal spray (MFNS). Methods A phase III, double-blind, randomized, placebo-controlled, multi-center study compared the efficacy of MFNS 200 mcg QD, dosed in the morning (AM), for treatment of ocular symptoms associated with SAR. Subjects were at least 12 years old with at least a 2-year history of SAR. In daily diaries, subjects evaluated AM ocular symptom severity on a scale of 0 (none) to 3 (severe) on treatment Days 1 to 15. Co-primary endpoints included change from baseline in average instantaneous (AM) total nasal symptom score (sum of individual nasal symptom scores for congestion, rhinorrhea, sneezing, and itching) and instantaneous (AM) total ocular symptom score (iTOSS) (sum of individual eye symptom scores for itching/burning, tearing/watering, redness), Days 2 to 15. Results Subjects (429) with similar baseline characteristics and moderate-to-severe ocular symptoms received MFNS 200 mcg QD or placebo. MFNS 200 mcg QD demonstrated superiority over placebo in least squares mean changes from baseline in subject-rated, average AM iTOSS from Day 2 to 15 (−1.71 [−25.1%] and −1.37 [−20.1%], respectively; P equal to 0.026). MFNS was well tolerated. Conclusions MFNS 200 mcg QD demonstrated statistically significant improvements in AM iTOSS associated with SAR. These are the first prospective results demonstrating that MFNS significantly reduces ocular symptoms in subjects with SAR.